Exploring the Potential Mechanism of Ru‐Pi‐Ning Granules Against Mammary Gland Hyperplasia Based on UPLC‐Q‐TOF‐MS and Network Pharmacology
Biomedical Chromatography · 2026-03 · 40 (3)
DOI: 10.1002/bmc.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 18.01.2026. Verfasst von Mengjun Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Mammary Glands, Animal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Clinical Research Project of Non-directly Affiliated Hospital of Anhui University of Chinese Medicine, Major Programs of Natural Science Research in Colleges and Universities in Anhui Province, Science Research Team Program of Anhui Colleges and University.
Abstract (Originalsprache)
Ru‐Pi‐Ning granules were a classic traditional Chinese medicine (TCM) prescription with good therapeutic effects on mammary gland hyperplasia (MGH). However, the main components and potential mechanisms of action of Ru‐Pi‐Ning were still unclear. This study aimed to preliminarily elucidate the potential mechanism of Ru‐Pi‐Ning in the treatment of MGH based on ultra‐high performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (UPLC‐Q‐TOF‐MS) and network pharmacology. Compounds in Ru‐Pi‐Ning were determined by UPLC‐Q‐TOF‐MS. A Venn diagram was created with drug targets and disease targets, and a PPI network diagram was constructed with shared targets using the STRING database. GO and KEGG pathway analysis were performed using the Metascape platform; molecular docking was carried out using AutoDockTools. A total of 127 active components and 75 overlapping genes were screened out. The main biological processes included cellular response to hormone stimulus and positive regulation of cell migration. Ru‐Pi‐Ning in treating MGH could regulate several signaling pathways, including the relaxin‐signaling pathway and HIF‐1 signaling pathway. The core targets were TP53, EGFR, and AKT1. Molecular docking indicated that the active compounds had good binding ability with the screened targets. Ru‐Pi‐Ning might exert its therapeutic effect on MGH through multiple components, multiple targets, and multiple pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
- UWE College of Hainan Medical University, Haikou, China.
- Taihe Country People's Hospital of Anhui Province, Fuyang, China.
- Taihe Hospital Affiliated to Wannan Medical College, Fuyang, China.
- Anhui Province Institute for Food and Drug Control, Hefei, China.
- Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.
ORCID-Profile: Xiaoqin Chu
Förderung
- Clinical Research Project of Non-directly Affiliated Hospital of Anhui University of Chinese Medicine
- Major Programs of Natural Science Research in Colleges and Universities in Anhui Province
- Science Research Team Program of Anhui Colleges and University
- 2025 Annual Hospital-based Scientific Research Projects of Taihe County People's Hospital
Zitieren
APA
Pan, M., Yan, C., Zhang, J., Li, X., Sun, L., Mao, C., Li, Z., & Chu, X. (2026). Exploring the Potential Mechanism of Ru‐Pi‐Ning Granules Against Mammary Gland Hyperplasia Based on UPLC‐Q‐TOF‐MS and Network Pharmacology. Biomedical Chromatography, 40(3). https://doi.org/10.1002/bmc.70356
Vancouver
Pan M, Yan C, Zhang J, Li X, Sun L, Mao C, et al. Exploring the Potential Mechanism of Ru‐Pi‐Ning Granules Against Mammary Gland Hyperplasia Based on UPLC‐Q‐TOF‐MS and Network Pharmacology. Biomedical Chromatography. 2026;40(3). doi:10.1002/bmc.70356
BibTeX
@article{Pan2026,
author = {Pan, Mengjun and Yan, Chujiami and Zhang, Jingli and Li, Xiang and Sun, Li and Mao, Caini and Li, Zhengguang and Chu, Xiaoqin},
title = {Exploring the Potential Mechanism of Ru‐Pi‐Ning Granules Against Mammary Gland Hyperplasia Based on UPLC‐Q‐TOF‐MS and Network Pharmacology},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {3},
doi = {10.1002/bmc.70356}
}
EUVIMED